tbuckley/cabot-search huggingface dataset:
Comparison of Physician and Computer Diagnostic Accuracy
Authors: Hannah L. Semigran, David M. Levine, Shantanu Nundy, Ateev Mehrotra
Journal: JAMA Internal Medicine (2016)

Across physicians, they were more likely to list the correct diagnosis first for high-acuity vignettes (vs low-acuity vignettes) and for uncommon vignettes (vs common vignettes).In contrast, symptom checkers were more likely to list the correct diagnosis first for low-acuity vignettes and common vignettes (Table 2).Discussion | In what we believe to be the first direct comparison of diagnostic accuracy, physicians vastly outperformed computer algorithms in diagnostic accuracy (84.3% vs 51.2% correct diagnosis in the top 3 listed). 4Despite physicians' superior performance, they provided the incorrect diagnosis in about 15% of cases, similar to prior estimates (10%-15%) for physician diagnostic error. 5While in this project we compared diagnostic performance, future work should test whether computer algorithms can augment physician diagnostic accuracy. 6ey limitations included our use of clinical vignettes, which likely do not reflect the complexity of real-world patients and did not include physical examination or test results.Physicians who chose to use Human Dx may not be a representative sample of US physicians and therefore may differ in diagnostic accuracy.Symptom checkers are only 1 form of computer diagnostic tools, and other tools may have superior performance.
TCT-232 Primary Percutaneous Coronary Intervention In Nonagenarian Patients With ST Elevation Myocardial Infarction: In-Hospital Mortality And Outcomes At One Year Follow-Up
Authors: Simone Muraglia, Riccardo Pertile, Giuseppe Braito, Michele Dallago, Alberto Menotti, Matteo Casavecchia, Silvano Piffer, Roberto Bonmassari
Journal: Journal of the American College of Cardiology (2015)
TCT-76 Six Versus Twelve Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable Polymer Sirolimus-Eluting Stents for Bifurcation Lesions: Insights From the I-LOVE-IT 2 Trial
Authors: Bo Xu, Changdong Guan, Kai Xu, Quanmin Jing, Yuejin Yang, Yaling Han
Journal: Journal of the American College of Cardiology (2015)
Trump and Clinton clash over Obamacare in second presidential debate
Authors: Jeanne Lenzer
Journal: BMJ (2016)

The US presidential nominees Hillary Clinton and Donald Trump revealed their conflicting stances over the future of President Barack Obama’s signature healthcare law in the second presidential debate held at Washington University in St Louis, Missouri, on Sunday 9 October.

The Democrats’ candidate, Clinton, vowed to fix the Affordable Care Act, while the Republican, Trump, promised to repeal and replace Obamacare with something much less expensive.

The two nominees squared off over healthcare in response to a question from a member of the public. In a town hall style event, Ken Karpowicz said, “The Affordable Care Act known as Obamacare—it is not affordable. Premiums have gone up, deductibles have gone up, copays [copayments] have gone up, prescriptions have …
Ten-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but reduced compared with psoriasis
Authors: Alexander Egeberg, Lone Skov, Yuki M.F. Andersen, Lotus Mallbris, Gunnar H. Gislason, Jonathan I. Silverberg, Jashin J. Wu, Jacob P. Thyssen
Journal: Journal of the American Academy of Dermatology (2016)
Late-Onset Neutropenia in Rituximab-Treated Lymphoma Patients: Lymphocyte Subpopulation Imbalances, Bone Marrow Hematopoiesis and Immunohistology.
Authors: Kostas Stamatopoulos, Theodora Papadaki, Charalambos Pontikoglou, Ioanna Athanasiadou, Niki Stavroyianni, Juergen Bux, Ioannis Batsis, Katerina Pyrovolaki, George Paterakis, Dimitra Anagnostou, Achilles Anagnostopoulos, Helen Papadaki
Journal: Blood (2007)
TCT-292 Comparison of Adenosine and Regadenoson for Measurement of Fractional Flow Reserve: Systematic Review and Meta-analysis
Authors: Justin Z. Lee, Iwan Nyotowidjojo, Seongseok Yun, See Wei Low, Huu Tam Truong, Marvin Slepian, David Fortuin, Kwan S. Lee
Journal: Journal of the American College of Cardiology (2015)
A Rare Case of Lateral Ectopic Thyroid
Authors: Rosa Maria Paragliola, Giampaolo Papi, Rosa Maria Lovicu, Alfredo Pontecorvi, Salvatore M. Corsello
Journal: Clinical Nuclear Medicine (2016)

Ectopic thyroid tissue is an abnormality caused by aberrant thyroid gland embryogenesis during its passage from the floor of the primitive foregut to its final position. The most frequent place of ectopic thyroid tissue is the base of tongue, whereas lateral thyroid gland is a very rare finding. The present case describes a case of thyroid dysgenesis, caused by a submandibular ectopic thyroid gland. Thyroid scintigraphy was crucial for the diagnosis: in fact, the patient was asymptomatic, and the diagnosis was performed only on the basis of subclinical hypothyroidism.
Self-interested agents create, maintain, and modify group-functional culture
Authors: Manvir Singh, Luke Glowacki, Richard W. Wrangham
Journal: Behavioral and Brain Sciences (2016)

Abstract We agree that institutions and rules are crucial for explaining human sociality, but we question the claim of there not being “alternatives to CGS [that] can easily account for the institutionalized cooperation that characterizes human societies” (target article, sect. 7). Hypothesizing that self-interested individuals coercively and collaboratively create rules, we propose that agent-based hypotheses offer viable alternatives to cultural group selection (CGS).
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Authors: Lori S. Hart, JulieAnn Rader, Pichai Raman, Vandana Batra, Mike R. Russell, Matthew Tsang, Maria Gagliardi, Lucy Chen, Daniel Martinez, Yimei Li, Andrew Wood, Sunkyu Kim, Sudha Parasuraman, Scott Delach, Kristina A. Cole, Shiva Krupa, Markus Boehm, Malte Peters, Giordano Caponigro, John M. Maris
Journal: Clinical Cancer Research (2016)

Purpose: Neuroblastoma is treated with aggressive multimodal therapy, yet more than 50% of patients experience relapse. We recently showed that relapsed neuroblastomas frequently harbor mutations leading to hyperactivated ERK signaling and sensitivity to MEK inhibition therapy. Here we sought to define a synergistic therapeutic partner to potentiate MEK inhibition.Experimental Design: We first surveyed 22 genetically annotated human neuroblastoma-derived cell lines (from 20 unique patients) for sensitivity to the MEK inhibitor binimetinib. After noting an inverse correlation with sensitivity to ribociclib (CDK4/6 inhibitor), we studied the combinatorial effect of these two agents using proliferation assays, cell-cycle analysis, Ki67 immunostaining, time-lapse microscopy, and xenograft studies.Results: Sensitivity to binimetinib and ribociclib was inversely related (r = -0.58, P = 0.009). MYCN amplification status and expression were associated with ribociclib sensitivity and binimetinib resistance, whereas increased MAPK signaling was the main determinant of binimetinib sensitivity and ribociclib resistance. Treatment with both compounds resulted in synergistic or additive cellular growth inhibition in all lines tested and significant inhibition of tumor growth in three of four xenograft models of neuroblastoma. The augmented growth inhibition was attributed to diminished cell-cycle progression that was reversible upon removal of drugs.Conclusions: Here we demonstrate that combined binimetinib and ribociclib treatment shows therapeutic synergy across a broad panel of high-risk neuroblastoma preclinical models. These data support testing this combination therapy in relapsed high-risk neuroblastoma patients, with focus on cases with hyperactivated RAS-MAPK signaling. Clin Cancer Res; 23(7); 1785-96. ©2016 AACR.
A new tandem autologous peripheral blood progenitor cell transplant (AT) approach incorporating total marrow irradiation (TMI) for patients (pts) with multiple myeloma (MM)
Authors: G. Somlo, P. Frankel, C. Karanes, A. Krishnan, P. Parker, L. Popplewell, F. Sahebi, R. Spielberger, S. Forman, J. Y. Wong
Journal: Journal of Clinical Oncology (2008)

8544 Background: Previous attempts to deliver total body irradiation and high-dose melphalan (MEL) as part of AT regimens have been unsuccessful. TMI using helical tomotherapy may improve the efficacy of MEL, and may cause less toxicity. Patients and Methods: We designed a phase I study for pts with stages I-III MM in response or with stable disease (SD) . Pts received MEL 200 mg/m2 and AT, followed by a tandem ablative regimen consisting of TMI and AT. Starting at 1000 cGy, dose levels were to be increased by 200 cGy per cohort up to 200 cGy twice daily×5 days. Following tandem AT, maintenance therapy consisted of dexamethasone 40 mg/day×4 days and thalidomide 50–200 mg/day for 6 months (mos) for pts in complete response (CR), or for a minimum of 12 mos for pts not in CR. Results: The median age was 53.5 years (35- 66). Twenty three pts (13 female, 10 male) with stages I (1 ), II (6), and III (16) MM received MEL at a median time of 10 mos (7–18) from diagnosis; 22 pts received TMI (1000 cGy through 1800 cGy); 1 pt did not received TMI due to post-MEL toxicities. The median time between MEL and TMI was 63.5 days (range, 44–119). Granulocyte recovery to >1000/microliter following Mel was 14 days (13–15) versus 15 days after TMI (range; 13–19). Platelet recovery to >20,000/microliter was identical: 13 days (range:0–16 versus 0–17). Reversible grade 3 non-hematologic toxicities by TMI dose levels included febrile neutropenia (levels 1 and 2: 1 pt each); none (level 3); fatigue (level 4: 1 pt). Dose limiting toxicities at level 5 (1800 cGy) included grade 3 abdominal pain requiring parenteral feeding (n:1) and grade 3 hypotension requiring pressor support (n:1), defining the maximum tolerated dose (MTD) at 1600 cGy. The estimated median radiation dose to normal organs was 14–64% of the targeted bone marrow dose in the 6 pts each treated at doses 1600 and 1800 cGy. Best responses included CR (n:6), very good partial response (VGPR, n:7) PR or SD (n:7), and 2 pts are too early to assess. At a median follow-up of 12 months (range, 1–24+ mos) 2 pts progressed (at 8 and 20 mos) and 11 pts continue on maintenance. Conclusion: We defined the MTD of TMI as 1600 cGy, and preliminary outcome is encouraging. A phase II trial of tandem AT with 1600 cGy of TMI is ongoing. No significant financial relationships to disclose.
Myeloablative Conditioning in Myelofibrosis using i.v. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation with High Doses of CD34+ Cells Results in Hematologic Responses - Follow-Up of Three Patients.
Authors: Stefan Fruehauf, Eike C. Buss, Julian Topaly, Hans H. Kreipe, Anthony D. Ho
Journal: Blood (2004)
Research of HIF-1 Mediated SDF-1/CXCR4 Axis on the Directional Migration and Neural Differentiation of Mesenchymal Stem Cells
Authors: Qin Yu, Jie Lin, Lizhen Liu, Peipei Li, XiaoBo Xuan, Yan Wang, YanPing Duan, Hui Dong
Journal: Blood (2010)
Surgical treatment of colorectal liver metastasis after neoadjuvant chemotherapy.
Authors: Milan Zegarac, Srdjan Nikolic, Igor Djurisic, Marko Buta
Journal: Journal of Clinical Oncology (2012)

688 Background: Liver is typical place for metastasis for patients with colorectal carcinoma. During the period of disease, 50% of patients with colorectal carcinoma will get liver metastases, 20% of the will have synchronous and 30% metachronous. Surgical resection is modality of choice in treatment for liver metastases in colorectal carcinoma. Applying neoadjuvant chemotherapy in patients with colorectal cancer liver metastases, which are primarily nonresectable or potentially resectable, it is possible to transform in resectable state. The goal of treatment is R0 liver resection and putting the patient in the NED stage of disease. Methods: All patients received protocol for potentially resectable metastase- FOLFOX-bevacizumab. The assessment was conducted on the basis of angioCT and NMR. With all patients liver resection procedures and RFA were applied. Results: During the period from June 2007 to December 2009 in 40 patients with nonresectable or potentially resectable metastases the neoadjuvant HT FOLFOX-bevacizumab was applied on average for three months. The patients were operated 6 weeks after the last application of bevacizumab, because of the possibility of intraoperative bleeding. The number of metastases ranged from 1 to 6. With 17 patients lobar resection was performed, and with 10 patients segmental resection was performed. With another 11 patients metastasectomy was performed, while RFA was performed with 2 patients. 3 years survival is 57.5%. Conclusions: By applying neoadjuvant HT and bevacizumab with patients suffering from colorectal cancer liver metastases as the only existing metastases, it is possible to significantly reduce metastases, and thereby resection as well. With this approach time without disease and survival are increased.
GW27-e0072 Effects of Iron Supplementation With and Without Docosahexaenoic Acid on the Cardiovascular Disease Risk Based on Paraoxonase-1, hs-CRP, and ApoB/ApoA-I Ratio in Women with Iron Deficiency Anemia
Authors: Farzad Shidfar, Samira Amani, Mohammadreza Vafa, Ramin Shekarriz, Sharieh Hosseini, Shahrzad Shidfar, Mohammadreza Eshraghian, Neda Mousavi
Journal: Journal of the American College of Cardiology (2016)
GW27-e0888 Comparation of the efficacy between pulmonary vein antral isolation plus high density left atrial voltage mapping and pulmonary vein isolation on paroxysmal atrial fibrillation
Authors: Yang Fangfang, Yangbo Xing, Chao Xu, Zhansheng Xiao, Fang Peng, Yufang Qiu, Hangyuan Guo
Journal: Journal of the American College of Cardiology (2016)
Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Cord Blood Transplantation (CBT). Retrospective Analysis on Behalf of Eurocord and the EBMT Autoimmune Diseases Working Party.
Authors: Thomas Daikeler, Myriam Labopin, Gérard Socié, Maura Faraci, Fawzi Abdel-Rahman, M. Akif Yesilipek, William Arcese, Anne O'Meara, Anne Sirvent, Jan Voswinkel, Amparo Verdeguer, Virginie Gandemer, Hélène Schoemans, Andrew J. Cant, Chiara Messina, Petr Sedlacek, Ajay J. Vora, Valerie Mialou, Jose Luis Díez, Federica Sorà, Charlotte Jubert, Andrée-Laure Herr, Annalisa Ruggeri, Alessandro Crotta, Eliane Gluckman, Dominique Farge, Vanderson Rocha
Journal: Blood (2010)
Two Years Versus Six Months of Oral Anticoagulation after a First Episode of Unprovoked Pulmonary Embolism: The Padis PE Multicenter, Double-Blind, Randomized Trial
Authors: Francis Couturaud, Olivier Sanchez, Gilles Pernod, Patrick Mismetti, Patrick Jego, Elisabeth Duhamel, Karine Provost, Claire Bal dit Sollier, Emilie Presles, Philippe Castellant, Florence Parent, Pierre-Yves Salaun, Luc Bressollette, Michel Nonent, Philippe Lorillon, Philippe Girard, Karine Lacut, Marie Guegan, Jean-Luc Bosson, Silvy Laporte, Christophe Leroyer, Herve Decousus, Guy Meyer, Dominique Mottier
Journal: Blood (2014)
TCT-675 New-onset intraventricular conduction delays with the Edwards Sapien 3 transcatheter aortic valve
Authors: Cristina Panico, Marco G. Mennuni, Marco Luciano Rossi, Dennis Zavalloni, Gabriele Luigi Gasparini, Margherita Soldi, Giulio G. Stefanini, Gianluigi Condorelli, Patrizia Presbitero, Paolo Pagnotta
Journal: Journal of the American College of Cardiology (2015)
Results of a phase Iib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma
Authors: U. Bogdahn, A. K. Mahapatra, V. Olyushin, V. Parfenov, G. Stockhammer, S. Ludwig, G. Wuerth, H. Heinrichs, K. H. Schlingensiepen
Journal: Journal of Clinical Oncology (2008)

2076 Background: High-grade gliomas (HGG) show an overexpression of TGF-beta 2. AP 12009 is a TGF-beta 2 specific inhibitor, which has been successfully tested in phase I/II studies in patients with recurrent or refractory HGG. Methods: The phase IIb study G004 was an international, open-label, randomized, active-controlled, dose-finding study in patients with recurrent or refractory HGG (WHO grades III and IV). Patients were randomized into 3 treatment groups. Main objective was to compare 2 doses of AP 12009 (10 μM=AP-10 or 80 μM=AP-80) and standard chemotherapy (TMZ or PCV) with regard to response rate, survival, and safety. AP 12009 was administered intratumorally by convection-enhanced delivery with up to 11 treatment cycles (7-d-on, 7-d-off / cycle. Results: Here we report on the subpopulation of patients with recurrent AA (WHO grade III, GBM patients see separate abstract). The AP-10 group showed an overall comparable safety profile as the control group. Although there was a higher incidence of SAEs in the AP 12009 groups, these were often procedure-related and mostly reversible. No drug-related SAEs were observed in any of the 3 treatment groups. The current median of survival times was higher in both AP 12009 groups than in the control group with a remarkable survival benefit of AP-10 over chemotherapy of 12.3 months. Furthermore, more individuals in the AP-10 group experienced long-term clinical benefit (CR+PR) and showed significantly more responders after 14 months. Dose finding was achieved, as efficacy and safety results for the AP-10 group were better than those of the AP-80 group. Conclusions: AP 12009 showed a positive risk-benefit profile and demonstrated an excellent potential as single agent for the treatment of recurrent or refractory AA patients, especially for the AP-10 group. A phase III study in patients with recurrent or refractory AA is planned to start in Q2 2008. Treatment group AP-10 (N=12) AP-80 (N=15) Control (N=12) Incidence of SAEs (%) 67 67 25 Related or possibly related 0 0 0 Current median of survival times (months) 34.0 31.7 21.7 Survival rate at 24 months (%) 83 53 42 Overall response rate (CR+PR) at 14 months (%) 42* 20 0* CR=complete response, PR=partial response, * significant difference between AP-10 and control (p<0.05) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Antisense Pharma Antisense Pharma GmbH Antisense Pharma Antisense Pharma GmbH
Activation of hedgehog pathway in neuroendocrine tumors.
Authors: Mei Dong, Takafumi Sangai, Qiang Zhao, Asif Rashid, Funda Meric-Bernstam, James C. Yao
Journal: Journal of Clinical Oncology (2012)

e14662 Background: Neuroendocrine tumors (NETs) are rare tumors and often follow an indolent course, especially the tumors of low-to-intermediate grade. Nonetheless, they are incurable and lethal when advanced. The genetic etiology of sporadic NET is largely unknown. Numerous established oncogenes and tumor suppressor genes have been studied, but no mutations have been consistently identified, indicating tumorigenesis of NET may follow distinct mechanisms. It is well known that significant amount of patients with NETs may have harbored the slow-growing lesions since very young age, suggesting it could result from alterations of pathways involved in development. Hedgehog (Hh) signaling has been found to be important in embryonic patterning, stem cell maintenance and tissue repair; and is normally silenced in most mature adult tissue. However, it frequently undergoes gain-of-function mutations or reactivation due to ligand overproduction and has been linked to the etiology of a variety of tumors. Specific inhibitors of Hh pathway have been developed and tested in clinical trials with very promising results. Methods: In this study, the functional status of Hh pathway was examined in archival tissue specimmen using immunohistochemistry and its role in tumorigenesis was tested using an xenograft mouse model. Results: we have found that Hh ligand is overproduced in 48% (27/52) of small bowel NETs, 28% (9/32) of pancreatic NETs, and 28.6% of lung carcinoids. Hh signaling blockade led to decreased survival of NET cells in vitro, and tumor shrinkage in vivo using a xenograft mouse model. Conclusions: we conclude that Hh pathway is involved in the tumorigenesis of NETs, and can be used as a potential therapeutic target for NETs.
TCT-735 The presence of concomitant chronic total occlusion in patients with ischemic heart failure is related with worse long-term outcomes – report from COMMIT-HF registry.
Authors: Mateusz Tajstra, Michal Hawranek, Lukasz Pyka, Adam Krajewski, Elzbieta Gadula-Gacek, Damian Pres, Andrzej Lekston, Marek Gierlotka, Mariusz Gasior
Journal: Journal of the American College of Cardiology (2015)
Intratumoral Heterogeneity of Pretreatment 18F-FDG PET Images Predict Disease Progression in Patients With Nasal Type Extranodal Natural Killer/T-cell Lymphoma
Authors: Kuan-Yin Ko, Chia-Ju Liu, Chi-Lun Ko, Ruoh-Fang Yen
Journal: Clinical Nuclear Medicine (2016)

Purpose The aim of this study was to investigate whether the textural features of pretreatment 18F-FDG PET images can predict prognosis for nasal type extranodal natural killer/T-cell lymphoma (ENKTL). Materials and Methods A retrospective analysis of the pretreatment 18F-FDG PET images of the patients with newly diagnosed nasal type ENKTL from 2008 to 2013 was conducted. Progression-free survival (PFS) was the main outcome measure. The primary tumor was identified and then delineated using the 40% maximum standardized uptake value (SUVmax) thresholding method. The textural features of the pretreatment 18F-FDG PET images were extracted. The prognostic significance of the textural features of the PET images were examined using the receiver operating characteristic (ROC) curves and Cox regression analysis. P values <0.05 were considered statistically significant. Results In total, 17 patients were enrolled, among whom 11 showed disease progression and 6 died from the disease during the median follow-up period of 27.2 months. Dissimilarity and low-intensity short-zone emphasis (LISZE) were identified as independent predictors of PFS by using the ROC curves and multivariate Cox analysis after adjusting for the clinical variables. Conclusions Dissimilarity and LISZE were the significant predictors of disease progression in patients with nasal type ENKTL and can improve their prognostic stratification.
Primary Central Nervous System Lymphomas (PCNSL) Are Distinct from Systemic DLBCL for Expression Pattern of Germinal Center and Activation B-Cell Markers. A GOELAMS Study.
Authors: Sophie Camilleri-Broet, Vincent Delwail, Anne Moreau, Martine Gardembas, Martine Raphael, Thierry Lamy, Catherine Sautes-Fridman, Philippe Colombat, Antoine Martin
Journal: Blood (2004)
The scalp hair collar and tuft signs: A retrospective multicenter study of 78 patients with a systematic review of the literature
Authors: Didier Bessis, Michèle Bigorre, Nausicaa Malissen, Guillaume Captier, Christine Chiaverini, Claire Abasq, Sébastien Barbarot, Olivia Boccara, Emmanuelle Bourrat, Hassan El Fertit, Catherine Eschard, Thomas Hubiche, Jean-Philippe Lacour, Nicolas Leboucq, Emmanuel Mahé, Stéphanie Mallet, Myriam Marque, Ludovic Martin, Juliette Mazereeuw-Hautier, Nathalie Milla, Alice Phan, Patrice Plantin, Marie-Christine Picot, Eve Puzenat, Valérie Rigau, Pierre Vabres, Sylvie Fraitag, Franck Boralevi
Journal: Journal of the American Academy of Dermatology (2016)